登录

会议嘉宾

  • Bruce Rosen, MD, PhD.
  • Matthew Anderson, MD, PhD.
  • Martha Herbert, M.D., Ph.D.
  • William Stone, Ph.D., ABPP-CN
  • Richard Frye, MD, PhD.
  • Valerie W. Hu, Ph.D.
  • June (Xuejun) Kong, M.D.
  • Cun-Jian Dong, PhD.
  • Dr. Albert Yeung
  • Jian Kong, MD, MS, MPH
  • Yumei Yao
  • Temple Grandin
  • Mike Zhaoxi Wang, MD, PhD
  • Qing-Mei Wang, MD, PhD, Spauding Rehab.
  • person
    • Bruce Rosen, MD, PhD. Dr. Rosen is Professor of Radiology at the Harvard Medical School and Professor of Health Science and Technology at the Harvard-MIT Division of Health Sciences and Technology. He is Director of the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital. Dr. Rosen is a world-leading expert in functional neuroimaging. Over the past thirty years he has pioneered the development and application of many novel physiological and functional nuclear magnetic resonance techniques to measure hemodynamic and metabolic changes associated with brain activation and cerebrovascular insult as well as complementary tools to measure microvascular and microstructural morphology. These and other techniques he has developed are used by research centers and hospitals throughout the world to study and evaluate patients with stroke, brain tumors, dementia, and neurologic and psychological disorders. Most recently, Dr. Rosen’s work has focused on the integration of fMRI data with information from other modalities, including positron emission tomography (PET), magnetoencephalography (MEG) and noninvasive optical imaging. By using fMRI tools to evaluate the linkage between neuronal and physiological (metabolic and hemodynamic) events during periods of increased neuronal activity, his studies will allow researchers to better interpret fMRI signal changes and develop new ways to probe brain function. Dr. Rosen leads the activities of several large interdisciplinary and inter-institutional research programs including the NIH Blueprint-funded Human Connectome Project, the NIBIB Regional Resource Center, the Center for Functional Neuroimaging Technologies (CFNT), and the Biomedical Informatics Research Network (BIRN) Collaborative Tools Support Network. He is Principal Investigator/Program Director for two neuroimaging training programs. He has authored more than 300 peer-reviewed articles as well as over 50 book chapters, editorials and reviews. Dr. Rosen is the recipient of numerous awards in recognition of his contributions to the field of functional MRI, including, most recently, the 2011 Outstanding Researcher award from the Radiological Society of North America (RSNA), and the Rigshospitalets International KFJ Prize from the University of Copenhagen/Rigshospitalet. Dr. Rosen is a Fellow and Gold Medal winner for his contributions to the field of Functional MRI from the International Society for Magnetic Resonance in Medicine, a Fellow of the American Institute for Medical and Biological Engineering, and a member of the Institute of Medicine of the National Academies.
    • Title of speech: advances in autism brain imaging studies
    person
    • Matthew Anderson, MD, PhD. Associate Professor of Harvard Medical school, and Principal Investigator in the Departments of Pathology and Neurology and Director of Neuropathology at Beth Israel Deaconess Medical Center. The Anderson Laboratory studies the molecular, cellular and neural network mechanisms responsible for disorders of membrane excitability and synaptic transmission in the central nervous system. See more at the site: http://www.bidmc.org/Research/Departments/Neurology/Laboratories/MatthewAndersonLaboratory.aspx#sthash.vJwNA8Oq.dpufIncreases of Ube3a gene dosage cause autism (maternal isodicentric chromosome 15 [idic15], maternal Ube3a triplication; Smith et al. Sci Transl Med), while maternal Ube3a loss causes Angelman syndrome. In mature neurons, Ube3a is expressed exclusively from the maternal allele; the paternal Ube3a allele is repressed. Ube3a acts as an E3 ubiquitin ligase but also separately as a transcriptional co-activator. To determine whether excess Ube3a causes autism behavioral deficits via actions in the neuronal cytoplasm/synapse or nucleus, he engineered a nuclear importing peptide signal to the C-terminus of Ube3a. We have further engineered the Ube3a transgene to permit neuron subtype and brain region specific increases of Ube3a gene dosage to enable circuit mapping of the autism-associated behavioral defects. A detailed analysis of circuit-specific changes in gene expression (ribotag) and physiology (optogenetic manipulations and neural circuit studies) will follow. He is also now investigating the neural circuit basis of increased aggression in this autism disorder. He is also investigating the function other autism genes with direct protein-protein interacts with the Ube3a-regulated genes to identify common autism pathways. In separate projects we are investigating the functional consequences of the genomic changes that occurred during hominid evolution and might underlie human cognitive abilities. Such changes are accompanied by altered gene expression in the cerebral cortex, so he is focused on a hominid-specific non-coding RNA altered as a CNV in autism. Genome editing and transcript profiling in cell lines explores the molecular mechanisms of the hominid-specific change in gene regulation. He introduce the hominid-specific changes into the mouse genome to reconstitute the molecular step in hominid evolution in a living lower mammal to permit detailed studies of behavior, circuit physiology, and gene expression. Speech title: Nucleating an Autism Gene Network
    person
    • Martha Herbert, M.D., Ph.D., Dr. Herbert is Assistant professor of neurology at Harvard Medical School and a pediatric neurologist at Massachusetts General Hospital, where she is the director of the TRANSCEND Research Program. She is the co-founder and co-director of body brain resilience center. She is an affiliate of the Harvard-MGH-MIT-HST Martinos Center for Biomedical Imaging. Dr. Herbert earned her medical degree at the Columbia University College of Physicians and Surgeons. Prior to her medical training she obtained a doctoral degree at the University of California, Santa Cruz, studying evolution and development of learning processes in biology and culture in the History of Consciousness program, and then did postdoctoral work in the philosophy and history of science. She trained in pediatrics at Cornell University Medical Center and in neurology and child neurology at Massachusetts General Hospital, where she has remained. She received the first Cure Autism Now Innovator Award and is on the Scientific Advisory Committee of Autism Speaks.
    • Title of speech: Autism revolution, a whole body approach
    person
    • William Stone, Ph.D., ABPP-CN, Dr. Stone is Director of Neuropsychology Training and Clinical Services, Massachusetts Mental Health Center (MMHC); Director of Neuropsychology Fellowship Program at MMHC and Beth Israel Deaconess Medical Center (BIDMC); Assistant Professor of Psychology, Harvard Medical School, staff clinical psychologist of department of psychiatry, BIDMC. His research is focused on identifying cognitive, clinical and biological risk factors for the development of psychiatric illness. These efforts emphasize attempts to identify liability syndromes for schizophrenia and related disorders. They also aim to develop interventions that will alter or prevent the trajectory to psychosis and other manifestations of major mental illness.
    • Title of speech: Early diagnosis of autism and guideline in USA
    person
    • Richard Frye, MD, PhD. Dr. Frye is the Director of Autism Research at Arkansas Children’s Hospital Research Institute and Director of the Autism Multispecialty Clinic at Arkansas Children’s Hospital in Little Rock, AR. Dr. Frye is a well-recognized expert in the diagnosis and treatment of Autism Spectrum Disorders (ASD) and other developmental disorders. Dr. Frye has a broad background including specific training in neurodevelopmental disorders, physiology, psychology, and biostatistics. He is fellowship trained in Behavioral Neurology and Psychology and has clinical expertise in the assessment, diagnosis, and treatment of children with ASD. While at the University of Texas he developed a medically-based autism clinic which was specifically designed to diagnose and treat neurological and metabolic abnormalities associated with ASD in order to improve quality of life and promote recovery. Over the past two years he has completed three clinical studies related to ASD, including an open-label trial examining the metabolic and behavioral effects of tetrahydrobiopterin, a clinical study of the metabolic and genetic characteristics of children with ASD and mitochondrial disease, and a clinical study on the prevalence of the folate receptor alpha autoantibody in children with ASD, as well as the response to leucovorin treatment in ASD children with the folate receptor alpha autoantibody. As Director of Autism Research at the Arkansas Children’s Hospital his goal is to develop an integrated autism program that includes a multi-specialty autism clinic, a translational research program focusing on biomarkers and clinical-trials, and a basic science program focusing on mitochondrial and redox metabolic metabolism.
    • Titles of speech: 1-2 of the following
    • Neurometabolic Disorders Associated with Autism
    • Mitochondrial Disorders in Autism
    • Cerebral Folate Deficiency in Autism
    • Treatable Disorders Associated with Autism
    person
    • Valerie W. Hu, Ph.D., is a Professor of Biochemistry and Molecular Medicine at The George Washington University School of Medicine and Health Sciences in Washington, DC as well as the mother of a son with an autism spectrum disorder (ASD). Dr. Hu was trained as a chemist, with a Ph.D. in Chemistry from the California Institute of Technology and a B.S. in Chemistry from the University of Hawaii. She has a long research history in cross-disciplinary studies focused on protein structure-function relationships and membrane-protein interactions. In late 2004, because of her personal interest in ASD, she redirected her research focus towards autism, with long-range goals of developing biomarker-based diagnosis and personalized treatment of autism spectrum disorders. Dr. Hu has since become a leader in the application of multi-disciplinary, integrative genomics approaches to ASD which involve the integration of large-scale data from gene expression, behavioral, genetic, and epigenetic analyses, which are described in 18 research articles and reviews published since 2006. She is also the sole editor and one of the chapter authors for a recently released book entitled: Frontiers of Autism Research: New Horizons for Diagnosis and Treatment” (World Scientific, May 2014).
    • Title of speech: “An integrated genomics approach towards understanding: What causes autism?”
    person
    • June (Xuejun) Kong, M.D. Dr. Kong is the founder and president of American Chinese Medical Exchange Society (ACMES), Faculty Physician and Researcher of Beth Israel Deaconess Medical Center, Harvard Medical School. As a mom of autistic son, to understand and cure autism became her lifetime passion and mission. Since 2000, she founded “Biomedical Solution of Autism”, “Institute to Cure Autism”, and co-founded “Body & Brain Resilience Center, autism family clinic”. She got extensively trained in autism related areas, she treated many autism individuals with not only biomedical but also integrative East meets West approaches, and conducted clinical or pre-clinical trials of many scientifically based treatments; She is a principal investigator for autism researches. Dr. Kong is not only a clinician, researcher, but also an executive leader and strong advocator, she organized many medical conference including international autism forums, Dr. Kong has brought together expert physicians, neuroscientists, neuroimaging specialists, psychologist, therapists, social workers to form clinical and research collaboration platform nationally and internationally, promote autism awareness and productive life. She is also founder and Editor-in-Chief of “North American Journal of Medicine & Science” and “North American Journal of Medicine & Health”, publishes autism special issues annually for the last 5 years with increasing impact.
    • Title of speech: biomedical /integrative treatment of autism
    person
    • Cun-Jian Dong, PhD. Dr. Dong was trained at top Chinese and US institutions and universities for his Master's and Ph.D. degrees and postdoctoral studies. He has been conducting translational research for nearly 20 years on understanding of neural injury mechanisms, disease pathogenesis, and development of new medicines for the treatment of CNS disease. He was a Research Investigator (a full professor level position) at Allergan Inc, a world top 500 multinational corporation. He is recognized internationally by his peers as an expert in neuroscience, particularly in the field of retinal neurobiology. He has also served as a guest reviewer of research grants for the US National Science Foundation, as well as for many international neuroscience and physiology journals. He is a member of the Society for Neuroscience, the Association for Research in Vision & Ophthalmology, and International Society for Clinical Electrophysiology of Vision. His expertise and experience include: 1) pathogenesis of CNS disease, particularly retinal disease, and identification, characterization, and validation in animal models of novel drug targets; 2) development of in vivo, in vitro models, and assays for efficacy and safety tests; 3) design of high-throughput compound screens, selection of hit compounds, optimization of lead compounds and drug candidates, determination of their pharmacokinetics and toxicity, and optimization of drug formulations; 4) neuropharmacology and neurophysiology; 5) recruitment, training, and management of a drug development team; 6) management and coordination of drug development projects; 7) formulation and implementation of intermediate and long strategic plans for the project team. Dr. Dong is the research investigator and consultant of To Cure Autism Institute.
    person
    • Dr. Albert Yeung is Director of Primary Care Research at the Depression Clinical and Research Program at Massachusetts General Hospital (MGH) and Associate Professor of Psychiatry at Harvard Medical School. He is the principal investigator of the study on “Evaluating changes in resting state networks before and after a Tai Chi training Intervention for Chinese Americans with depression”. Dr. Yeung obtained his medical degree from National Taiwan University. He also obtained a Doctor of Science degree with a major in epidemiology from Harvard School of Public Health. He completed residency training in psychiatry at MGH. Dr. Yeung's major research interests include integrating primary care and mental health services to improve treatment of depression, mental health issues of under-served populations, and the use of complementary and alternative methods in treating mood and anxiety disorders. He has authored or co-authored over 80 original articles, numerous book chapters, and a book on self-management of depression.
    • Title of speech: "The use of tai chi for treatment of autism"
    person
    • Jian Kong, MD, MS, MPH, Associate professor of Harvard Medical School, Researcher scientist, Massachusetts General Hospital, his primary interest focuses on the brain mechanisms of pain and pain modulation. He is particularly interested in using combined brain imaging tools to investigate how noxious information is processed in the brain, how noxious information can be modulated by treatment (acupuncture) and the mind (placebo and nocebo), how the mind and acupuncture interact during this modulation process, and how acupuncture is different placebo. In addition, he is also interested in the brain network evoked by acupuncture stimulation and the reliability of the activation pattern in both healthy and patient’s population; and the brain modulation effect of meditation and Tai Chi practice. He has published more than 70 papers in above fields. Recently, he is also interested in the empathy & appraisal of pain, placebo analgesia in patients with Autism, as well as the treatment of autism using alternative medicine.
    • Title of speech: brain imaging studies related acupuncture, pain and autism
    person
    • Yumei Yao, Board Certified Behavior Analyst (BCBA) , Wachusett Regional School District in Massachusetts as a district BCBA. She received her bachelor's degree in school education at Eastern China Normal University in Shanghai, China in 1988, received Master's degree in education at Widener University in Pennsylvania, US in 1996. After graduated from Widener University, she shifted her career from regular education to special education and joined The New England Center for Children (NECC) in Massachusetts: necc.org. NECC is a nationally well-known private, non-profit organization that leads research and education in the field of special education in the U.S. During the 10 years working at NECC, she not only gained the clinical experience of working/educating students with autism and other disabilities from age 4 to 22, but also enrolled in an advanced training program at Northeastern University and completed the course requirements for sitting in the exam of BCBA. She received my BCBA in 2007. She then worked at Marlborough Public School District from 2008-2013. During that time period she had opportunities to learn the public education laws and regulations in Special Education in Massachusetts. She also completed nine courses in School Administration in a CAGS program (Certificate of Advanced Graduate Study) at American International College. Working as an ABA Program Specialist for 5 years in Marlborough school district, she has many opportunities to apply her knowledge and experiences gained at NECC. She also learned different philosophies between private schools and public schools and how strictly we should follow the Commonwealth Massachusetts Regulations and Laws (CMR) and to use CMR to guide our educational and clinical practices. Currently she is a BCBA Consultant providing ABA services (Applied Behavior Analysis) to 13 schools (pre-K to post graduate high school) in Wachusett School District to special education teachers, related service providers and building administrators. She also work as a home-based supervisor at ACCEPT Education Collaborative to provide various modules of home services to 16 school districts at home settings.
    • Title of speech: 1-2 of the following:
    • 1. Overview of Autism and ABA
    • 2. What is IEP and How to Develop an IEP
    • 3. Functions of Behavior and How to Decrease Challenging Behavior
    • 4. Discrete Trial Teaching and Task Analysis
    • 5. Preference Assessment and Picture Activity Schedule
    • 6. Communication Skills and AAC
    • 7. How to Measure Behaviors
    • 8. Reinforcement and Behavior Change
    person
    • Temple Grandin,PhD, Professor of animal science at Colorado State University, a best-selling author, an autistic activist, and a consultant to the livestock industry on animal behavior. She also invented the "hug box", a device to calm those on the autism spectrum. The subject of an award-winning, 2010 biographical film, Temple Grandin, she also was listed in the Time 100 list of the one hundred most influential people in the world in the "Heroes" category. Grandin was born in Boston, Massachusetts, was diagnosed with autism as a child and went on to pursue work in psychology and animal science. She has become a leading advocate for autistic communities and has also written books and provided consultation on the humane treatment of animals. As a high-functioning autistic person, Grandin has been able to make sense of and articulate her unusual life experiences with rare depth. In 2010, HBO released an Emmy Award winning film on Grandin’s life. In 2009, she was named a fellow of the American Society of Agricultural and Biological Engineers. She is the recipient of several honorary degrees, and has been featured on a range of television and radio programs.
    person
    • Mike Zhaoxi Wang, MD, PhD, Research Scientist at public health and education, Harvard School of Public Health. He was trained in Beijing Medical University, Uniformed Services University of the Health Science (Bethesda, MD)and John Hopkins University. His researches involve gene mapping in complex human diseases, and other translational medicine projects funded by NIH.
    person
    • Qing-Mei Wang, MD, PhD, Spauding Rehab. Dr. Qing Mei Wang obtained her PhD and MD at University of Medicine and Dentistry of New Jersey and completed her residency training in Physical Medicine and Rehabilitation Program at Mount Sinai Medical Center at NY. She holds an academic appointment in the Department of Physical Medicine and Rehabilitation at Harvard Medical School and is an attending physician at Spaulding Rehabilitation Hospital. Her clinical focus is on stroke rehabilitation. She also conducts clinical and basic research to investigate the pathophysiology of ischemic stroke and mechanism of stroke recovery. She is principal investigator of Stroke Biological Recovery Laboratory. Her research is funded by NIH grant.
    Date 2015.7.31-2015.8.3
    City China·Shenzhen
    Contact
    Contact: teacher Liu
    Phone: 0755-25162109
    Mobile: 13602606456
    Email: meeting@acmes.net
    MATERNAL&CHILD HEALTH HOSPITAL
    Contact: teacher Lin
    Phone: 0755-83228832
    Email: meeting@acmes.net
    Contact
    Contact: E Xie
    Phone: 0755-25162109
    Email: meeting@acmes.net
    Participating Univeristy
    Participating Institutions
    Participating Hospitals
    Conference Organizers
    Shenzhen Government
    American Chinese Medical Exchange Society